[Federal Register Volume 59, Number 165 (Friday, August 26, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-21100]


[[Page Unknown]]

[Federal Register: August 26, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

 

Manufacturer of Controlled Substances; Application

    Pursuant to Sec. 1301.43(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 15, 1994, Celgene 
Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, made 
application to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the Schedule I controlled 
substance 2,5-Dimethoxyamphetamine (7396). Celgene Corporation plans to 
manufacture small quantities of the above controlled substance 
utilizing bio-catalysis to develop, manufacture and sell high value-
added compounds important to pharmaceutical and agrochemical 
industries.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the above application and may also file a written 
request for a hearing thereon in accordance with 21 CFR 1301.54 and in 
the form prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, United States Department of 
Justice, Washington, DC 20537, Attention: DEA Federal Register 
Representative (CCR), and must be filed no later than September 26, 
1994.


    Dated: August 22, 1994.
Gene R. Haislip,
Deputy Assistance Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 94-21100 Filed 8-25-94; 8:45 am]
BILLING CODE 4410-09-M